Eijsink JFH, Al Khayat MNMT, Boersma C, et al. - Researchers investigated the public-health and economic impact of HCV screening and subsequent treatment with new direct-acting antivirals (DAAs) among pregnant women in the Netherlands. For this purpose, they developed an HCV natural history Markov transition state model. Along with all 179,000 pregnant women in the Netherlands (cohort 1), 3 further cohorts were modelled: all 79,000 first-time pregnant women (cohort 2), 33,000 pregnant migrant women (cohort 3) and 16,000 first-time pregnant migrant women (cohort 4). Analysis of each cohort in various scenarios was done: i no intervention, ie, the current practice, ii screen-and-treat, ie, the most extensive approach that involves treating all individuals identified HCV-positive, and iii screen-and-treat/monitor, ie, a strategy involving therapeutic management of symptomatic (F1–F4) patients and follow-up of asymptomatic (F0) HCV carriers with subsequent treatment only at progression. Findings support the cost-effectiveness of implementing universal screening for HCV among all pregnant women in the Netherlands. However, they suggest considering smaller risk groups as reasonable, given the budget impact of the intervention.